摘要
目的观察华蟾素注射液联合TACE治疗中晚期原发性肝癌的临床疗效。方法选择确诊为中晚期原发性肝癌患者78例,随机分为华蟾素联合治疗组和TACE单纯治疗组两组。结果联合组和对照组有效率差异无统计学意义,但华蟾素治疗组患者的生活质量明显高于单纯治疗组,而且12个月以上的生存率显著高于对照组;治疗3个周期后,联合组患者的各项实验室指标优于对照组,差异有统计学意义。结论 TACE联合华蟾素治疗肝癌可以减轻TACE对肝功能的损害程度,同时提高机体免疫功能,延长生存期,是中晚期肝癌一种较理想的治疗方法。
Objective To observe the clinical effect of Cinobufagin Injection combined with transcathete rarterial chemoembolization（TACE） on treating primary liver cancer.Methods 78 patiens with moderate and advanced primary liver cancer were randomly divided into treatment group which treated 38 patients by Cinobufagin Injection combined with TACE,and control group,which treated 40 patients by TACE only.Results The life quality of patients in treatment group was obviously higher than that in control group,and the over-12-month survival rate of treatment group was significantly higher than that of control group,while the difference of the effective rate between the two groups had no statistically significant.The laboratory tests after three cycles of treatment group were better than that of control group,and the difference between the two groups was statistically significant.Conclusion Cinobufagin Injection combined with TACE can decrease the damage on liver by TACE,prolong survival time,and improve body immunity.
出处
《中国实用医药》
2011年第34期1-2,共2页
China Practical Medicine
关键词
华蟾素
原发性肝癌
肝动脉化疗栓塞
Cinobufagin Injection
Primary liver cancer
Transcatheter arterial chemoembolization
